 to try to create a platform for discussion and innovation about new post-transplant medications. And the FDA statement pointed out that the agency, it says, is committed to the integrity of the so-called accelerated approval program to bring safe and effective drugs to market. Now, we briefly mentioned this accelerated approval program earlier in the show, but I wonder, Dr. Newell,